COVID-19 Frontliners: Searching for the Silver Bullet
Clinical trial leader Annie Luetkemeyer, MD, tests promising therapies for COVID-19 – and soon a vaccine.
![Portrait of Annie Luetkemeyer in a lab coat.](/sites/default/files/styles/news_card__image/public/2020-07/annie-luetkemeyer-frontliners-covid-card.jpg)
University of California San Francisco
Give to UCSFClinical trial leader Annie Luetkemeyer, MD, tests promising therapies for COVID-19 – and soon a vaccine.
How I learned to use social media to advance the public’s understanding of COVID-19.
As the United States’ testing regime floundered early in the pandemic, scientists at UCSF and the Chan Zuckerberg Biohub created from scratch a diagnostic lab that became a model for the nation.
The finding could offer additional insights into other immune conditions, including a type of childhood leukemia and the severe inflammation response in some children with COVID-19.
Depending on a cancer’s tissue of origin, tumors cause widespread and variable disruption of the immune system throughout the body, not just at the primary tumor site.
Cancer specialists from UCSF will present new research findings at the annual scientific program of the American Society of Clinical Oncology, the world’s largest clinical cancer research meeting.
Cancer and autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis, might not seem to have much in common, but some researchers now are pinning hopes on the same immune system cell –
A project launched by UC San Francisco and UC Berkeley scientists evaluated some of the more than 120 available antibody test kits.
UCSF researchers now have reported a new method to design and test cell therapies, one they expect will speed the development of new life-saving treatments not only for cancer, but for other diseases, too.
A simple urine test can diagnose and predict acute rejection in kidney transplants, leading to an opportunity for earlier detection and treatment, according to a new study by researchers at UCSF.
UCSF scientists found that an early-life window of immune tolerance available to a normally harmless bacterial species is firmly closed to another, often pathogenic species — one that is a leading cause of drug-resistant skin infections in the U.S. and occasional source of “flesh-eating” necrosis.
In a breakthrough with important implications for the future of immunotherapy for breast cancer, UCSF scientists have found that blocking the activity of a single enzyme can prevent a common type of breast cancer from spreading to distant organs.
UC San Francisco and the Translational Research Institute for Space Health are co-sponsoring the inaugural Space Health Innovation Conference to advance research and scientific understanding of how space travel impacts health.
Now in its sixth year, the Best Global Universities rankings focus on schools’ academic research and reputation.
Using advanced technology, scientists have discovered an autoimmune disease that appears to affect men with testicular cancer.
Properly caring for the skin with a moisturizing cream may lower inflammation levels and potentially prevent age-related diseases, according to a new clinical pilot study.
UCSF scientists have used the CRISPR-Cas9 gene-editing system to create the first pluripotent stem cells that are functionally “invisible” to the immune system.
UCSF discovery that may lead to new treatments for people with IPF.
In laboratory experiments, UCSF researchers successfully beat back the growth of aggressive liver cancers using a surprising new approach.
Researchers have discovered that the intestine is the source of immune cells that reduce brain inflammation in people with MS, and that increasing the number of these cells blocks inflammation entirely.
From sensory processing disorder to how CRISPR is being explored to bring new treatments to patients, these are the stories that most engaged our readers in 2018.